Physician profile
Robin O Stemerman
NPI 1003589763
$1,040.26
in general payments reported to CMS, 2019-2025
12 companies · $79.37 in 2025
The $79.37 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.78 · 2022: $401 · 2023: $363 · 2024: $155 · 2025: $79.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $580.08 | 2022-2025 | Brilinta, Andexxa, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.44 | 2022-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $78.84 | 2022-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $70.83 | 2024 | |
| Chiesi USA, INC. | $51.21 | 2022-2023 | Cleviprex, Kengreal |
| Alexion Pharmaceuticals, INC. | $32.40 | 2021-2023 | Ultomiris |
| Teleflex LLC | $30.60 | 2022 | |
| Abbvie INC. | $26.99 | 2025 | |
| Pfizer INC. | $26.73 | 2021 | |
| Melinta Therapeutics, LLC | $23.04 | 2025 | Rezzayo, Kimyrsa |
| Bayer Healthcare Pharmaceuticals INC. | $19.82 | 2024 | |
| Molnlycke Health Care US, LLC | $12.28 | 2024 | Tortoise Turning & Positioning System, Mlnlyckez-Flo Fluidized Positioner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Stemerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.